Phosphorylation of Glycogen Synthase Kinase-3 and Stimulation of T-cell Factor Signaling Following Activation of EP2 and EP4 Prostanoid Receptors by Prostaglandin E2
Overview
Affiliations
Recently we have shown that the FP(B) prostanoid receptor, a G-protein-coupled receptor that couples to Galpha(q), activates T-cell factor (Tcf)/lymphoid enhancer factor (Lef)-mediated transcriptional activation (Fujino, H., and Regan, J. W. (2001) J. Biol. Chem. 276, 12489-12492). We now report that the EP(2) and EP(4) prostanoid receptors, which couple to Galpha(s), also activate Tcf/Lef signaling. By using a Tcf/Lef-responsive luciferase reporter gene, transcriptional activity was stimulated approximately 10-fold over basal by 1 h of treatment with prostaglandin E(2) (PGE(2)) in HEK cells that were stably transfected with the human EP(2) and EP(4) receptors. This stimulation of reporter gene activity was accompanied by a PGE(2)-dependent increase in the phosphorylation of both glycogen synthase kinase-3 (GSK-3) and Akt kinase. H-89, an inhibitor of protein kinase A (PKA), completely blocked the agonist-dependent phosphorylation of GSK-3 in both EP(2)- and EP(4)-expressing cells. However, H-89 pretreatment only blocked PGE(2)-stimulated Lef/Tcf reporter gene activity by 20% in EP(4)-expressing cells compared with 65% inhibition in EP(2)-expressing cells. On the other hand wortmannin, an inhibitor of phosphatidylinositol 3-kinase, had the opposite effect and inhibited PGE(2)-stimulated reporter gene activity to a much greater extent in EP(4)-expressing cells as compared with EP(2)-expressing cells. These findings indicate that the activation of Tcf/Lef signaling by EP(2) receptors occurs primarily through a PKA-dependent pathway, whereas EP(4) receptors activate Tcf/Lef signaling mainly through a phosphatidylinositol 3-kinase-dependent pathway. This is the first indication of a fundamental difference in the signaling potential of EP(2) and EP(4) prostanoid receptors.
Nishibata T, Amino N, Tanaka-Kado R, Tsujimoto S, Kawashima T, Konagai S Biomed Res Int. 2023; 2023:7133726.
PMID: 38058393 PMC: 10697779. DOI: 10.1155/2023/7133726.
Attiq A, Afzal S Front Pharmacol. 2023; 14:1255727.
PMID: 37680708 PMC: 10482416. DOI: 10.3389/fphar.2023.1255727.
Yudhawati R, Shimizu K Int J Mol Sci. 2023; 24(8).
PMID: 37108459 PMC: 10138595. DOI: 10.3390/ijms24087299.
Kanno T, Nakagawa N, Aonuma T, Kawabe J, Yuhki K, Takehara N Heart Vessels. 2022; 38(4):606-613.
PMID: 36522555 PMC: 9986202. DOI: 10.1007/s00380-022-02219-4.
Wang P, Li X, Zhu Y, Wei J, Zhang C, Kong Q Front Vet Sci. 2022; 9:932034.
PMID: 36268046 PMC: 9578681. DOI: 10.3389/fvets.2022.932034.